Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Patient with Three EGFR Mutations - Gradual Development of Resistance to Previous Targeted Treatment].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 1 Jan 2000

Svatoň Martin, Pešek Miloš, Baxa Jan, Mukenšnabl Petr, Benešová Lucie, Minárik Marek

Abstract excerpt

BACKGROUND: Patients with sensitive EGFR mutations are already being treated with first and second generation tyrosine kinase inhibitors (TKIs). However, resistance to these drugs occurs over time, and over half of all cases is caused by a mutation (T790M) in the EGFR kinase domain. Osimertinib offers a new treatment option that overcomes this problem. Unfortunately, resistance to this drug also develops after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Piperazines

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29488779
DOI: 10.14735/amko201853

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Patient with Three EGFR Mutations - Gradual Development of Resistance to Previous Targeted Treatment].PMID 29488779Read ↗

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature reviewSemantic proximity Read ↗

Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.Semantic proximity Read ↗

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].Semantic proximity Read ↗

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case ReportSemantic proximity Read ↗

Temporal Heterogeneity of ROS1 Fusion and Braf Fusion Conferred Resistance to First-and Third-generation EGFR Tkis: a Case Report.Semantic proximity Read ↗

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.Semantic proximity Read ↗

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment StrategySemantic proximity Read ↗

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.Semantic proximity Read ↗

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Semantic proximity Read ↗

Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.Semantic proximity Read ↗

[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].Semantic proximity Read ↗

[Management of patients with resistance to EGFR-TKI].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.